title: [Prevention of early-onset group B streptococcus neonatal diseases. The 2005 experience of the Lille University Health Center].
abstract: OBJECTIVE
  To study the efficiency of the official recommendations on the prevention of group B streptococcus and the impact of this strategy.
  
  
  METHODS
  A prospective study was realized in 2005. All infants who were live-born at the Jeanne-de-Flandre hospital (Lille, France) and their mothers were included in the study. Data concerned both pregnancy (vaginal screening, intrapartum antibiotic) and newborn (safe, colonization and early-onset neonatal bacterial disease).
  
  
  RESULTS
  Our study included 4353 mother-newborn couples. Vaginal screening was performed on 92% of the women included in the study. Prevalence of vaginal group B streptococcus in screened women was 7%. Perpartum antibioprophylaxia of group B streptococcus was achieved in 12% of the women included in the study. Group B streptococcus was associated to 60% of probable and certain early-onset bacterial neonatal diseases, with an incidence of 9/1000 births. Exposition to antenatal antibiotherapy multiplied by two the risk of ampicillin resistant Gram-negative bacilli (RR=2 [1.1-3.8]).
  
  
  CONCLUSIONS
  Recommendations were well followed, but in our health center group, B streptococcus was the main bacteria responsible for early-onset bacterial neonatal diseases. Because of the risk of germ selection, a more targeted antibioprophylaxia has to be preferred.
authors.affiliation: Pédiatrie en maternité, hôpital Jeanne-de-Flandre, centre hospitalier régional universitaire de Lille, 59037 Lille cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Thibaudon Baveux
authors.forename: A
authors.initials: A
authors.lastname: Stroebel Noguer
authors.forename: I
authors.initials: I
authors.lastname: Boulard Mallet
authors.forename: M
authors.initials: M
authors.lastname: Djavadzadeh-Amini
authors.forename: N
authors.initials: N
authors.lastname: Kacet
authors.forename: P
authors.initials: P
authors.lastname: Truffert
authors.forename: D
authors.initials: D
authors.lastname: Subtil
authors.forename: J-P
authors.initials: JP
authors.lastname: Dubos
mesh_terms: D000328:Adult; D019072:Antibiotic Prophylaxis; D005260:Female; D005602:France; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000382:microbiology / Q000517:prevention & control*; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008403:Mass Screening; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000382:microbiology* / Q000517:prevention & control; D011446:Prospective Studies; D013290:Streptococcal Infections / Q000175:diagnosis / Q000188:drug therapy*; D013292:Streptococcus agalactiae / Q000302:isolation & purification; D014623:Vaginal Diseases / Q000175:diagnosis / Q000382:microbiology